Bilder RM (1997). Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 42:255-264. Cancro R, Lehmann HE (2000). Schizophrenia: Clinical features. In Sadock BJ, Sadock VA (eds). Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 7th ed. Lippincott, Williams, and Wilkins: Philadelphia, pp. 1169-1199. Carson WH, Ali M, Saha GC, Dunbar GC, Ingenito G (2001). A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Presented at the annual meeting of the American Psychiatric Association, May 7-12, 2001, New Orleans. Casey DE (1995). Motor and mental aspects of EPS. Int Clin Psychopharmacol, 10:105-114. Casey DE, Daniel D, Tracy K, Wozniak P, Sommerville K (2001). Improved antipsychotic effect of divalproex combined with risperidone or olanzapine for schizophrenia. Presented at the World Assembly of Mental Health, Vancouver, July 22-27, 2001. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia. Am J Psychiatry 158:518-526.

Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-485. Delay J, Deniker P (1952). Le traitement des psychoses par une methode neurolyque derivee de l'hibernotherapie. Congres des Medicins Alienistes et Neurologistes de France. Masson Editeurs Libraires de France: Paris, pp. 497-502. DeQuardo JR, Tandon R (1998). Do atypical antipsychotic medications favorably alter the long-

term course of schizophrenia? J Psychiatr Res 32:229-242. Fink M, Sackeim HA (1996). Convulsive therapy in schizophrenia? Schizophr Bull 22:27-42.

Geddes JR, Harrison PJ (1997). Closing the gap between research and practice. Br J Psychiatry 171:220-225.

Gilbert PL, Harris MJ, McAdams LA, et al. (1995). Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Arch Gen Psychiatry 52:173-181.

Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377.

Greden JF, Tandon R (1995). Long-term treatment for lifetime disorders. Arch Gen Psychiatry 52:197-200.

Haase HJ, Janssen PAJ (1958). The Action of Neuroleptic Drugs: A Psychiatric, Neurologic, and Pharmacological Investigation. Year Book Medical Publishers, Chicago Amsterdam.

Harvey PD, Keefe RSE (1997). Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums 2:41-55.

Jain KK (2000). An assessment of iloperidone in the treatment of schizophrenia. Expert Opin Investigat Drugs 9:2935-2943.

Jibson MD, Tandon R (1998). New atypical antipsychotic medications. J Psychiatr Res, 32: 215-228.

Jibson MD, Tandon R (2000). Treatment of schizophrenia. Psychiatr Clin North Am, Annual of Drug Therapy 7:83-113.

Jones B, Taylor CC, Meehan K (2001). The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry (Suppl 2):22-24.

Kales HC, DeQuardo JR, Tandon R (1999). Combined electroconvulsive therapy and clozap-ine in treatment-resistant schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 23: 547-555.

Kane JM (1999). Pharmacologic treatment of schizophrenia. Biol Psychiatry 46:1396-1408.

Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.

Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA (1993). Does clozapine cause tardive dyskinesia? J Clin Psychiatry 54:327-330.

Keefe RSE, Silva SG, Perkins DO, Lieberman JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 25:201-222.

Kraepelin E (1919). Dementia Praecox and Paraphrenia. Translated by Barclay RM and Robertson GM. Edinburgh, E and S Livingstone.

Lehman AF, Steinwachs DM (1998). Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 24: 1-10.

Maixner SM, Mellow AM, Tandon R (1999). The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry 60(Suppl 8):29-43.

Mellman TA, Miller AL, Weissman EM, Crismon ML, Essock SM, Marder SR (2001). Evidence-based pharmacological treatment for people with severe mental illness: A focus on guidelines and algorithms. Psychiatric Services 52:619-625.

Meltzer HY (1995). The concept of atypical antipsychotics. In den Boer JA, Westenberg HGM, van Praag HM (eds). Advances in the Neurobiology of Schizophrenia. Wiley: Chichester, pp. 265-273.

Miller DD, Tandon R (2000). The biology and pathophysiology of negative symptoms. In Keefe R, McEvoy J (eds). Negative Symptoms of Schizophrenia. American Psychiatric Press: Washington DC.

Mojtabai R, Nicholson RA, Carpenter BN (1998). Role of psychosocial treatments in management of schizophrenia: A meta-analytic review of controlled outcome studies. Schizophr Bull 24:569-587.

Otani K, Aoshima T (2000). Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monitoring 22:118-121.

Seeman P, Lee M, Chau-Wong M, et al. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-720.

Slade M, Priebe S (2001). Are randomized controlled trials the only gold that glitters. Br J Psychiatry 179:286-287.

Sumiyoshi T, Matsui M, Yamashita I (2001). The effect of tandospirone, a serotonin (1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49:861 -868.

Swift RH, Harrigan EP, van Kammen DP (1998). A comparison of intramuscular ziprasidone and intramuscular haloperidol. 9th Congress of the Association of European Psychiatrists, Copenhagen, 20-24 September.

Tandon R (1999). Cholinergic aspects of schizophrenia. Br J Psychiatry 174(suppl 37):7-11.

Tandon R, Greden JF (1989). Cholinergic hyperactivity and negative schizophrenic symptoms: A model of dopaminergic/cholinergic interactions in schizophrenia. Arch Gen Psychiatry 46:745-753.

Tandon R, Milner K, Jibson MD (1999a). Antipsychotics from theory to practice: Integrating clinical and basic data. J Clin Psychiatry 60(Suppl 8):20-28.

Tandon R, Taylor SF, DeQuardo JR, Eiser A, Jibson MD, Goldman M (1999b). The cholinergic system in schizophrenia reconsidered. Neuropsychopharmacology 22:S189-202.

Tandon R, Glick I, Goldman M, Jibson MD, Marder SR, Mellman T (2001). Managing Schizophrenia: A Comprehensive Primer. McMahon: New York.

0 0

Post a comment